EUVIMEDOdkrijte EUVIMED
Klinische StudieRandomisierte kontrollierte Studie

Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study

M Inoue, Y Tanaka, N Sugita, M Yamasaki, T Yamanaka, J Minagawa, K Nakamuro, T Tani, Y Okudaira, T Karita

Biotherapy · 1993

DOI: 10.1007/bf01877381 ↗

At a glance

Klinische Studie in Biotherapy, 1993. Written by M Inoue and 9 co-authors. Institution: Department of Obstetrics and Gynecology, Osaka University Medical School. Cited 31 times so far (Crossref); 16 references.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

The effect of immunotherapy using sizofiran (SPG) on the prognosis of patients with ovarian cancers was prospectively studied in a total of 68 patients, who were randomly assigned to either a cisplatin, adriamycin and cyclophosphamide (PAC) therapy group or a PAC plus SPG combination therapy group. The survival rate was significantly higher in patients with stage Ic, II or III cancers treated with the PAC plus SPG combination, compared with the patients treated with PAC alone. In the SPG-receiving patients with stage Ic or more advanced cancers who were treated with four cycles or more of PAC, the outcome was improved (Cox-Mantel, p = 0.074; generalized Kruskal-Wallis, p = 0.032). Similar improvement was also observed in the patients with non-serous adenocarcinomas (Cox-Mantel, p-0.076; generalized Kruskal-Wallis, p = 0.045). No side effects attributable to SPG were recorded. The present results suggest that the use of SPG in combination with long-term chemotherapy improves the postoperative prognosis in ovarian cancer patients.

Subjects

MeSH terms (MEDLINE)

Adjuvants, ImmunologicAntineoplastic Combined Chemotherapy ProtocolsCisplatinCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHumansMiddle AgedOvarian NeoplasmsPrognosisProspective StudiesSizofiran

Substances

Adjuvants, ImmunologicSizofiranDoxorubicinCyclophosphamideCisplatin

Authors and institutions

  • Department of Obstetrics and Gynecology, Osaka University Medical School.

Cite

APA

Inoue, M., Tanaka, Y., Sugita, N., Yamasaki, M., Yamanaka, T., Minagawa, J., Nakamuro, K., Tani, T., Okudaira, Y., & Karita, T. (1993). Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study. Biotherapy. https://doi.org/10.1007/bf01877381

Vancouver

Inoue M, Tanaka Y, Sugita N, Yamasaki M, Yamanaka T, Minagawa J, et al. Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study. Biotherapy. 1993. doi:10.1007/bf01877381

BibTeX
@article{Inoue1993,
  author = {Inoue, M and Tanaka, Y and Sugita, N and Yamasaki, M and Yamanaka, T and Minagawa, J and Nakamuro, K and Tani, T and Okudaira, Y and Karita, T},
  title = {Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study},
  journal = {Biotherapy},
  year = {1993},
  doi = {10.1007/bf01877381}
}
Start for free →